Latent tuberculosis infection and diagnostic performance of the tuberculin skin test among type 2 diabetics in Sana’a city, Yemen.

Publication date: Sep 19, 2024

Tuberculosis (TB) is one of the most widespread infectious diseases worldwide, typically persisting in the body as a latent TB infection (LTBI). Patients with type 2 diabetes have an increased risk of LTBI progressing to active TB. Therefore, this study determined the prevalence and predictors of LTBI and assessed the agreement between tuberculin skin test (TST) and interferon-gamma release assay (IGRA) in diagnosing LTBI among type 2 diabetics in Sana’a city, Yemen. A cross-sectional study was conducted among 150 type 2 diabetics in private health facilities in Sana’a in 2023. Data about demographics, diabetes-related characteristics, and potential risk factors for LTBI were collected using a structured questionnaire. Patients were then screened for LTBI using TST and IGRA. Univariate analysis was used to identify LTBI-associated risk factors, and multivariable binary logistic regression was used to identify independent predictors of LTBI. The agreement between TST and IGRA for diagnosing LTBI was assessed using Cohen’s kappa coefficient (_705). LTBI was prevalent among 29. 3% of type 2 diabetics using both types of tests (25. 3% with IGRA and 21. 3% with TST). Male gender was an independent predictor of LTBI (AOR = 4. 4, 95% confidence interval: 1. 30-15. 08; P = 0. 018). However, being employed (AOR = 0. 3, 95% CI: 0. 09-0. 75; P = 0. 013) and longer duration since diabetes diagnosis (AOR = 0. 3, 95% CI: 0. 12-0. 98; P = 0. 046) were identified as predictors of lower LTBI risk. The agreement between TST and IGRA for the diagnosis of LTBI was 88%, with a good and statistically significant agreement between the two test types (_705 = 0. 670; P 

Open Access PDF

Concepts Keywords
Diabetics Adult
Private Aged
Tuberculosis Cross-Sectional Studies
Worldwide Diabetes Mellitus, Type 2
Yemen Female
Humans
Interferon-gamma release assay
Interferon-gamma Release Tests
Latent Tuberculosis
Latent tuberculosis infection
Male
Middle Aged
Prevalence
Risk Factors
Tuberculin skin test
Tuberculin Test
Type 2 diabetics
Yemen
Yemen

Semantics

Type Source Name
disease MESH Latent tuberculosis infection
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH infectious diseases
disease MESH infection
disease MESH type 2 diabetes
pathway REACTOME Release
disease IDO assay
pathway REACTOME Reproduction
disease MESH latent infection
drug DRUGBANK Trestolone
disease IDO country
drug DRUGBANK Coenzyme M
disease MESH death
disease IDO infectious agent
disease MESH COVID 19
drug DRUGBANK BCG vaccine
disease IDO immunosuppression
disease MESH Diabetes mellitus
pathway REACTOME Immune System
disease IDO susceptibility
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Gold
disease IDO blood
drug DRUGBANK Heparin
disease MESH hives
disease MESH inflammation
disease MESH tic
disease MESH marital status
disease IDO history
drug DRUGBANK Serine
drug DRUGBANK Piroxicam
drug DRUGBANK Ademetionine
disease MESH missed diagnoses
disease MESH privacy
disease MESH morbidities
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease IDO host
disease IDO pathogen
drug DRUGBANK Glycine
drug DRUGBANK Medical air
drug DRUGBANK Guanosine
disease IDO cell
drug DRUGBANK Tropicamide

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *